Paperbox Health, an alumnus of the VITA Accelerator 2022 Program, has secured €230K in a bridge round

The Turin-based startup, known for its accessible screening method for learning disorders, closed a bridge round of 230k EUR as a follow-on from VITA Accelerator and GeneRa. Paperbox was born during the first edition of Vento, a non-profit venture builder supported by Exor Ventures. It underwent VITA Accelerator’s digital health program in 2022, facilitated by CDP Venture Capital Accelerator’s network, Healthware Group, and Accelerace.

In the previous year, GeneRa invested in Paperbox, with Alice Ravizza joining as PRRC (Person Responsible for Regulatory Compliance) to bolster the startup’s expertise and expedite the medical certification process for their dyslexia solution, DINO by Paperbox.

Recently, Paperbox announced a collaboration with GDMH, the digital medicine and health unit of IRCCS Policlinico Gemelli, to commence pre-clinical usability tests of DINO by Paperbox, a step toward medical device certification. Additionally, the public release of the tool for sector professionals is slated for 2024.

Paperbox aims to create an "end-to-end" solution for early identification and preventive intervention of childhood cognitive disorders, offering a preventive "smart treatment" path post-diagnosis.
The funds raised will be allocated to preparing and submitting the clinical trial for ethics committee approval, further solution development, go-to-market validation, and expanding the user base of speech and learning disorder therapists.

DINO by Paperbox has undergone testing with over 300 children aged 5–7 in 13 schools and by 30+ specialists, yielding promising results.

Meanwhile, VITA Accelerator is accepting applications for its 2024 program, welcoming startups in the digital health space.